NASDAQ:URGN - UroGen Pharma Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $40.50
Forecasted Upside: 134.92 %
Number of Analysts: 2
Breakdown:
0 Sell Ratings
0 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$17.24 As of 06/24/2021 05:30 PM ET

▲ +0.48 (2.86%)

1 month | 3 months | 12 months

Get New UroGen Pharma Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for URGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for URGN

^$40.50

▲ +134.92% Upside Potential

This price target is based on 2 analysts offering 12 month price targets for UroGen Pharma in the last 3 months. The average price target is $40.50, with a high forecast of $50.00 and a low forecast of $26.00. The average price target represents a 134.92% upside from the last price of $17.24.

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in UroGen Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/27/2021	HC Wainwright	Lower Price Target	Buy	$57.00 ➝ $50.00	Low
3/16/2021	HC Wainwright	Reiterated Rating	Buy		Low
1/14/2021	HC Wainwright	Reiterated Rating	Buy		High
11/10/2020	Oppenheimer	Lower Price Target		$48.00 ➝ $40.00	Low
9/21/2020	JPMorgan Chase & Co.	Lower Price Target		$31.00 ➝ $26.00	Medium
9/8/2020	HC Wainwright	Reiterated Rating	Buy		Medium
8/10/2020	Stifel Nicolaus	Reiterated Rating	Buy	$46.00	High
5/8/2020	HC Wainwright	Reiterated Rating	Buy		Low
5/7/2020	Stifel Nicolaus	Reiterated Rating	Buy	$46.00	Low
5/7/2020	Oppenheimer	Initiated Coverage	Buy	$47.00	Low
4/17/2020	Oppenheimer	Boost Price Target	Outperform	$45.00 ➝ $47.00	High
4/16/2020	HC Wainwright	Boost Price Target		$53.00 ➝ $57.00	High
4/15/2020	Stifel Nicolaus	Reiterated Rating	Buy		High
4/13/2020	HC Wainwright	Reiterated Rating	Buy	$75.00 ➝ $53.00	High
4/6/2020	Oppenheimer	Lower Price Target	Outperform	$47.00 ➝ $45.00	High
3/4/2020	HC Wainwright	Reiterated Rating	Buy	$75.00	High
3/2/2020	Stifel Nicolaus	Reiterated Rating	Buy	$40.00	High
1/16/2020	Cowen	Reiterated Rating	Buy		High
1/13/2020	Oppenheimer	Lower Price Target	Outperform	$62.00 ➝ $52.00	High
1/9/2020	National Securities	Initiated Coverage	Neutral	$37.00	Medium
12/19/2019	HC Wainwright	Reiterated Rating	Buy	$75.00	High
11/27/2019	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
11/13/2019	Oppenheimer	Lower Price Target		$70.00 ➝ $62.00	Low
11/13/2019	JPMorgan Chase & Co.	Lower Price Target	Neutral	$40.00 ➝ $39.00	Medium
11/11/2019	Cowen	Reiterated Rating	Buy		Medium
10/21/2019	HC Wainwright	Set Price Target	Buy	$75.00	Low
10/20/2019	Stifel Nicolaus	Set Price Target	Buy	$41.00	Low
9/24/2019	Cowen	Reiterated Rating	Buy		Medium
9/24/2019	Stifel Nicolaus	Reiterated Rating	Buy	$61.00	High
5/30/2019	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$41.00	Medium
5/29/2019	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$50.00 ➝ $50.00	High
5/28/2019	HC Wainwright	Set Price Target	Buy	$75.00	High
5/6/2019	Cowen	Reiterated Rating	Buy		Medium
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Low
3/5/2019	Stifel Nicolaus	Reiterated Rating	Buy	$63.00	High
3/1/2019	Raymond James	Set Price Target	Buy	$57.00	Low
3/1/2019	HC Wainwright	Reiterated Rating	Buy	$75.00	Medium
2/28/2019	Oppenheimer	Set Price Target	Buy	$70.00	Medium
1/29/2019	HC Wainwright	Initiated Coverage	Buy	$82.00	Low
11/13/2018	Oppenheimer	Set Price Target	Buy	$75.00	High
11/8/2018	Jefferies Financial Group	Initiated Coverage	Buy	$77.00	High
9/13/2018	Stifel Nicolaus	Initiated Coverage	Buy	$70.00	Medium
8/14/2018	Oppenheimer	Set Price Target	Buy	$75.00	High
8/14/2018	Cowen	Reiterated Rating	Buy		High
5/22/2018	Oppenheimer	Set Price Target	Buy	$75.00	Medium
5/15/2018	Oppenheimer	Set Price Target	Buy	$75.00	High
5/15/2018	Cowen	Reiterated Rating	Buy		High
4/4/2018	UBS Group	Upgrade	Market Perform ➝ Outperform		High
4/4/2018	Raymond James	Upgrade	Market Perform ➝ Outperform		High
4/3/2018	Oppenheimer	Reiterated Rating	Buy	$62.00 ➝ $75.00	High
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Low
3/19/2018	Jefferies Financial Group	Reiterated Rating	Buy		Low
3/16/2018	LADENBURG THALM/SH SH	Reiterated Rating	Buy ➝ Buy	$65.00	High
3/15/2018	Oppenheimer	Set Price Target	Buy	$62.00	High
1/2/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy ➝ Buy	$50.00	High
11/15/2017	Cowen	Reiterated Rating	Buy		N/A
11/15/2017	CIBC	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $51.00	N/A
11/15/2017	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
11/15/2017	UBS Group	Downgrade	Outperform ➝ Market Perform		N/A
11/14/2017	Oppenheimer	Set Price Target	Outperform	$32.00 ➝ $51.00	N/A
10/9/2017	Jefferies Financial Group	Boost Price Target	Buy	$27.00 ➝ $37.00	N/A
8/14/2017	Oppenheimer	Set Price Target	Buy	$32.00	High
5/30/2017	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$25.00	High
5/30/2017	Oppenheimer	Initiated Coverage	Outperform	$32.00	High
5/30/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$27.00	High
5/30/2017	Cowen	Initiated Coverage	Outperform		High

(Data available from 6/24/2016 forward)

UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Today's Range

Now: $17.24

$16.82

$17.51

50 Day Range

MA: $18.08

$15.20

$20.94

52 Week Range

Now: $17.24

$14.66

$28.52

Volume

61,128 shs

Average Volume

170,795 shs

Market Capitalization

$360.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of UroGen Pharma?

The following Wall Street sell-side analysts have issued research reports on UroGen Pharma in the last year: HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for URGN.

What is the current price target for UroGen Pharma?

4 Wall Street analysts have set twelve-month price targets for UroGen Pharma in the last year. Their average twelve-month price target is $40.50, suggesting a possible upside of 134.9%. HC Wainwright has the highest price target set, predicting URGN will reach $50.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $26.00 for UroGen Pharma in the next year.
View the latest price targets for URGN.

What is the current consensus analyst rating for UroGen Pharma?

UroGen Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe URGN will outperform the market and that investors should add to their positions of UroGen Pharma.
View the latest ratings for URGN.

What other companies compete with UroGen Pharma?

Other companies that are similar to UroGen Pharma include uniQure, Precigen, Arcutis Biotherapeutics, Innoviva, Kronos Bio, COMPASS Pathways, Stoke Therapeutics, Northwest Biotherapeutics, Nurix Therapeutics, ImmunoGen, Design Therapeutics, Edgewise Therapeutics, Vectura Group, Zealand Pharma A/S and Day One Biopharmaceuticals.

How do I contact UroGen Pharma's investor relations team?

UroGen Pharma's physical mailing address is 400 Alexander Park, Princeton NJ, 08540. The company's listed phone number is 646-768-9780 and its investor relations email address is [email protected] The official website for UroGen Pharma is www.urogen.com.